Stryker to host investor day
Portage, Michigan, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will host an Investor Day on Thursday, November 13, 2025, at 2:30 p.m. Eastern Time, in Mahwah, New Jersey.
Fiscal Year: January - December
Stryker Corporation (SYK), listed on the NYSE, has a market capitalization of $. As of Aug 19, 2025, the stock is trading at $381.61 per share, offering investors a clear view of its current market value. Stryker Corporation is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 50.54, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Stryker Corporation also offers a dividend yield of 0.88%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Stryker Corporation (SYK) may be overvalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Stryker Corporation is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Stryker Corporation, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Stryker Corporation is 36.26, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Stryker Corporation (SYK) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Stryker Corporation (SYK) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be overvalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Stryker Corporation (SYK) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Stryker Corporation. To access the full SS Score, consider upgrading your subscription.
Stryker Corporation is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 50.54. Investors should compare these metrics with industry peers to gauge whether Stryker Corporation is outperforming or underperforming within its sector.
Portage, Michigan, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will host an Investor Day on Thursday, November 13, 2025, at 2:30 p.m. Eastern Time, in Mahwah, New Jersey.
Portage, Michigan, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2025 Wells Fargo Securities Healthcare Conference on Thursday, September 4, at the Encore Boston Harbor....
BALTIMORE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Longeviti Neuro Solutions, a neurotechnology company with a focus on innovative platform solutions for complex brain disorders, today announces the appoint...
Portage, Michigan, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable October 31, 2025, to sharehol...
Stryker Corporation (NYSE:SYK) Q2 2025 Earnings Conference Call July 31, 2025 4:30 PM ET Company Participants Jason Beach - Vice President of Finance & Investor Relations Kevin A. Lobo - Chairman, CE...
Stryker raised its annual profit forecast and beat quarterly profit estimates on Thursday, banking on strong demand for its medical and surgical devices.
Portage, Michigan, July 31, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2025: Second Quarter Results Reported net sales increased 11.1% to $6.0 bil...
PORTAGE, Mich. , July 29, 2025 /PRNewswire/ -- Inari Medical, now part of Stryker (NYSE: SYK), a global leader in medical technologies, announced the launch of its next-generation InThrill Thrombectom...
Discover comprehensive insights with the "North America Cystoscopes Market Outlook to 2033" report. Analyze market data, company shares, and segment details for Flexible and Rigid Cystoscopes. Develop...
Portage, Michigan, July 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its second quarter of fiscal year 2025 on Thursday, July 31, 2025. A press ...
PORTAGE, Mich.--(BUSINESS WIRE)--Stryker received FDA 510(k) clearance for its Incompass® Total Ankle System, intended for patients with severe arthritis-related ankle joint damage.
The best fund managers are scaling back in these expensive stocks this year. 00:00 Introduction 00:39 Netflix NFLX 01:23 Mastercard MA 02:07 Stryker SYK Susan Dziubinski: I'm Susan Dziubinski with Mor...
Stryker's first basivertebral nerve ablation system targets the basivertebral nerve to provide relief from chronic* vertebrogenic low back pain. PORTAGE, Mich.
xAI Holdings led performance, driven by rapid AI innovation, Grok 3 launch, and the strategic acquisition of X, enhancing data access and integration. Spotify delivered strong results with margin expa...
Stryker Corporation (NYSE:SYK) Bank of America Securities 2025 Global Healthcare Conference May 13, 2025 4:40 PM ET Company Participants Preston Wells - Chief Financial Officer Jason Beach - Vice Pre...
I am downgrading Stryker Corporation to a Hold rating with a fair value of $380 per share, despite strong performance and growth prospects. Stryker's Mako spine and shoulder applications are set to la...
Stryker Corporation (NYSE:SYK) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Kevin Lobo - Chair and Chief Executive Officer Jason Beach - Vice President, Finance and In...
Stryker beat Wall Street estimates for quarterly profit on Thursday, fueled by strong demand for its medical and surgical devices.
Portage, Michigan, May 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2025: First Quarter Results Reported net sales increased 11.9% to $5.9 billio...
Portage, Michigan, April 29, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the Bank of America Securities 2025 Global Healthcare Conference on Tuesday, May 13, 2025, at the Encore at...
VB Spine is a Strategic Partner to Stryker with Access to Mako Spine and Copilot Marc, John and Anthony Viscogliosi Lead VB Spine as Co-Chief Executive Officers NEW YORK, April 01, 2025 (GLOBE NEWSWIR...
Portage, Michigan, April 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the sale of its U.S. spinal implants business ...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
Year | FCF Estimate | % | # Analysts |
---|---|---|---|
2025 | 3.95B | 13.17% | Est @13.2% |
2026 | 4.41B | 11.64% | Analyst x3 |
2027 | 5.28B | 19.82% | Analyst x2 |
2028 | 5.68B | 7.66% | Est @7.7% |
2029 | 6.03B | 6.10% | Est @6.1% |
2030 | 6.31B | 4.70% | Est @4.7% |
2031 | 6.56B | 3.98% | Est @4.0% |
2032 | 6.79B | 3.48% | Est @3.5% |
2033 | 7.01B | 3.13% | Est @3.1% |
2034 | 7.19B | 2.69% | Est @2.7% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
Year | FCF | Discount Factor | PV of Future FCF |
---|---|---|---|
2023A | 3.14B | 1.00 | 3.14B |
2024A | 3.49B | 1.00 | 3.49B |
2025E | 3.95B | 1.08 | 3.64B |
2026E | 4.41B | 1.17 | 3.75B |
2027E | 5.28B | 1.27 | 4.15B |
2028E | 5.68B | 1.38 | 4.12B |
2029E | 6.03B | 1.49 | 4.04B |
2030E | 6.31B | 1.62 | 3.90B |
2031E | 6.56B | 1.75 | 3.74B |
2032E | 6.79B | 1.90 | 3.57B |
2033E | 7.01B | 2.06 | 3.40B |
2034E | 7.19B | 2.23 | 3.22B |
Terminal | 125.80B | 2.23 | 56.35B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.